NCT03828292 · OUTCOME
Part 1: Trough Plasma Concentration (Ctrough) Following Repeat Dose Administration of Belantamab Mafodotin (ADC)
An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments · Source last updated 2025-08-19
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- GEOMETRIC_MEAN
- Unit
- ug/mL
- Interval / dispersion
- Geometric Coefficient of Variation
- Time frame
- Cycle 1, Cycle 2, Cycle 5, Cycle 8 and Cycle 11
What was measured
Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods.
Analysis population: Pharmacokinetic population. Only those participants with data available at specified time points have been analyzed.
Groups in this outcome
Main Study - Part 1: Belantamab Mafodotin 2.5 Milligram/ Kilogram (mg/kg)
Participants with Relapsed or Refractory Multiple Myeloma (RRMM) received belantamab mafodotin as 2.5 milligram (mg)/kilogram (kg) dose via intravenous (IV) infusion on Day 1 of every 21-day cycle (Q3W) maximum up to disease progression.
Main Study - Part 1: Belantamab Mafodotin 3.4 mg/kg
Participants with RRMM received belantamab mafodotin as dose of 3.4 mg/kg via IV infusion on Day 1 of every 21-day cycle (Q3W) maximum up to disease progression.
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
| Group | Source count |
|---|
| Main Study - Part 1: Belantamab Mafodotin 2.5 Milligram/ Kilogram (mg/kg) | 3 |
|---|
| Main Study - Part 1: Belantamab Mafodotin 3.4 mg/kg | 3 |
|---|
Reported measurements
CYCLE 1
Analysis denominator · Participants
| Group | Source count |
|---|
| Main Study - Part 1: Belantamab Mafodotin 2.5 Milligram/ Kilogram (mg/kg) | 3 |
|---|
| Main Study - Part 1: Belantamab Mafodotin 3.4 mg/kg | 3 |
|---|
Values in ug/mL · Interval/dispersion: Geometric Coefficient of Variation| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Main Study - Part 1: Belantamab Mafodotin 2.5 Milligram/ Kilogram (mg/kg) | 1.45 | 29.42 | Not reported | Not reported | Not reported |
|---|
| Main Study - Part 1: Belantamab Mafodotin 3.4 mg/kg | 1.39 | 109.19 | Not reported | Not reported | Not reported |
|---|
CYCLE 2
Analysis denominator · Participants
| Group | Source count |
|---|
| Main Study - Part 1: Belantamab Mafodotin 2.5 Milligram/ Kilogram (mg/kg) | 2 |
|---|
| Main Study - Part 1: Belantamab Mafodotin 3.4 mg/kg | 1 |
|---|
Values in ug/mL · Interval/dispersion: Geometric Coefficient of Variation| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Main Study - Part 1: Belantamab Mafodotin 2.5 Milligram/ Kilogram (mg/kg) | 2.41 | 75.30 | Not reported | Not reported | Not reported |
|---|
| Main Study - Part 1: Belantamab Mafodotin 3.4 mg/kg | 1.76 | Not reported | Not reported | Not reported | Not reported |
|---|
CYCLE 5
Analysis denominator · Participants
| Group | Source count |
|---|
| Main Study - Part 1: Belantamab Mafodotin 2.5 Milligram/ Kilogram (mg/kg) | 1 |
|---|
| Main Study - Part 1: Belantamab Mafodotin 3.4 mg/kg | 1 |
|---|
Values in ug/mL · Interval/dispersion: Geometric Coefficient of Variation| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Main Study - Part 1: Belantamab Mafodotin 2.5 Milligram/ Kilogram (mg/kg) | 3.17 | Not reported | Not reported | Not reported | Not reported |
|---|
| Main Study - Part 1: Belantamab Mafodotin 3.4 mg/kg | 2.20 | Not reported | Not reported | Not reported | Not reported |
|---|
CYCLE 8
Analysis denominator · Participants
| Group | Source count |
|---|
| Main Study - Part 1: Belantamab Mafodotin 2.5 Milligram/ Kilogram (mg/kg) | 1 |
|---|
| Main Study - Part 1: Belantamab Mafodotin 3.4 mg/kg | 0 |
|---|
Values in ug/mL · Interval/dispersion: Geometric Coefficient of Variation| Group | Value | Spread | Lower | Upper | Comment |
|---|
| Main Study - Part 1: Belantamab Mafodotin 2.5 Milligram/ Kilogram (mg/kg) | 3.60 | Not reported | Not reported | Not reported | Not reported |
|---|
CYCLE 11
Analysis denominator · Participants
| Group | Source count |
|---|
| Main Study - Part 1: Belantamab Mafodotin 2.5 Milligram/ Kilogram (mg/kg) | 0 |
|---|
| Main Study - Part 1: Belantamab Mafodotin 3.4 mg/kg | 0 |
|---|
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 29.42
- value
- 1.45
- group Id
- OG001
- spread
- 109.19
- value
- 1.39
- denoms
- counts
- group Id
- OG000
- value
- 3
- group Id
- OG001
- value
- 3
- units
- Participants
- title
- CYCLE 1
- categories
- measurements
- group Id
- OG000
- spread
- 75.30
- value
- 2.41
- group Id
- OG001
- value
- 1.76
- denoms
- counts
- group Id
- OG000
- value
- 2
- group Id
- OG001
- value
- 1
- units
- Participants
- title
- CYCLE 2
- categories
- measurements
- group Id
- OG000
- value
- 3.17
- group Id
- OG001
- value
- 2.20
- denoms
- counts
- group Id
- OG000
- value
- 1
- group Id
- OG001
- value
- 1
- units
- Participants
- title
- CYCLE 5
- denoms
- counts
- group Id
- OG000
- value
- 1
- group Id
- OG001
- value
- 0
- units
- Participants
- title
- CYCLE 8
- denoms
- counts
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- units
- Participants
- title
- CYCLE 11
- denoms
- counts
- group Id
- OG000
- value
- 3
- group Id
- OG001
- value
- 3
- units
- Participants
- description
- Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods.
- dispersion Type
- Geometric Coefficient of Variation
- groups
- description
- Participants with Relapsed or Refractory Multiple Myeloma (RRMM) received belantamab mafodotin as 2.5 milligram (mg)/kilogram (kg) dose via intravenous (IV) infusion on Day 1 of every 21-day cycle (Q3W) maximum up to disease progression.
- id
- OG000
- title
- Main Study - Part 1: Belantamab Mafodotin 2.5 Milligram/ Kilogram (mg/kg)
- description
- Participants with RRMM received belantamab mafodotin as dose of 3.4 mg/kg via IV infusion on Day 1 of every 21-day cycle (Q3W) maximum up to disease progression.
- id
- OG001
- title
- Main Study - Part 1: Belantamab Mafodotin 3.4 mg/kg
- param Type
- GEOMETRIC_MEAN
- population Description
- Pharmacokinetic population. Only those participants with data available at specified time points have been analyzed.
- reporting Status
- POSTED
- time Frame
- Cycle 1, Cycle 2, Cycle 5, Cycle 8 and Cycle 11
- title
- Part 1: Trough Plasma Concentration (Ctrough) Following Repeat Dose Administration of Belantamab Mafodotin (ADC)
- type
- SECONDARY
- unit Of Measure
- ug/mL
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle